Navigation Links
Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
Date:9/23/2009

NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced results of the Open Label Extension (OLE) trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The OLE trial, conducted in Taiwan, enrolled 29 of the 37 Taiwanese patients that had completed the randomized, multi-center, multi-national (United States and Taiwan) dose-ranging Phase 2 study. This OLE represents the first trial to examine the long-term safety and efficacy of Zerenex as a phosphate binder. The treatment period in all previous Zerenex Phase 2 clinical trials did not exceed 28 days.

The OLE trial provided for a daily dose, ranging from 2 to 6 g/day of Zerenex, for a period of up to one year following completion of the 28-day, dose-ranging Phase 2 study. The average duration of the patients' participation in the OLE trial was 306 +/- 85 days.

Data from the OLE trial indicate that the mean serum phosphorus level throughout the trial was 5.22 +/- 0.18 mg/dL, and the mean product of calcium times phosphate (CaxP) was 49.06 +/- 2.15 mg(2)/dL(2), both within the normal range as recommended by the KDOQI guidelines. In addition, during the OLE trial, the administration of IV iron as a supplement was withheld in 8 patients (27.6%) for periods ranging from 3 to 6 months and the administration of EPO was withheld in 8 patients (27.6%) for short periods because the hemoglobin, hematocrit, and iron parameters were within normal clinical ranges as assessed by the investigator. There were no signs of potential iron overload in the study patients, and there were no Zerenex-related serious adverse events as noted by either the pati
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- Fenwal Inc., a global leader focused on improving ... its commitment to provide blood centers with Alyx® system ... new lawsuit filed yesterday against Fenwal by Haemonetics Corporation ... 2003, is an advanced medical instrument used worldwide to ... donor in about 30 minutes. ,, Fenwal ...
(Date:12/15/2009)... West Pharmaceutical Services, Inc. (NYSE: WST ) ... payment of the first-quarter 2010 cash dividend of $0.16 ... 3, 2010 to shareholders of record on January 20, ... is a global manufacturer of components and systems for ... and closures and disposable components used in syringe, IV ...
(Date:12/15/2009)... Calif., Dec. 15 Dakim, Inc. and Alzheimer,s ... for Loved Ones, Brain Health Contest, designed to help ... of dementia and Alzheimer,s disease. All five winners will ... designed specifically to help seniors preserve their brain health ... in senior living communities across the country. ...
Breaking Medicine Technology:Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 35 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3New Target May Be Eyed in Kids Brain Cancer 62748 1New Target May Be Eyed in Kids Brain Cancer 62748 2Self Help for the Elderly and the Congress of California Seniors to Announce Expansion of Partnership With Verizon on Dec 8 to Raise Awareness of Eld 62743 1The Countrys Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 62738 1The Countrys Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 62738 2The Countrys Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 62738 3
(Date:12/15/2009)... new electrophoretic method for detecting MIRCERA and other ... using SARCOSYL-PAGE, has specifically enhanced sensitivity for MIRCERA, ... SDS-PAGE for detecting other EPOs. Details of ... World Anti-Doping Agency (WADA), appear in the latest ... published by Wiley-Blackwell. , MIRCERA (methoxy polyethylene glycol-epoetin ...
(Date:12/15/2009)... 15 The failure of the U.S. ... cut costs, much less the more effective direct ... latest example of how big industry controls the ... proposed drug amendment by Senator Dorgan (D-ND) was ... campaign pledge to allow Medicare to directly negotiate ...
(Date:12/15/2009)... 15 SUMMARY: The U.S. ... Protection and Affordable Care Act that would have ... for the safe and legal importation of lower ... by AARP and sponsored by Senators Dorgan, Snowe, ... and helped to bring down the skyrocketing costs ...
(Date:12/15/2009)... State Authority, Ban on Annual Benefit Limits, & ... Consumer Watchdog condemned the removal of ... and the public option from the U.S. Senate ... the Senate must still make three essential fixes ... the entire health care system to the insurance ...
(Date:12/15/2009)... Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged ... today announced that shareholders had approved all three resolutions that the Company had proposed at ... follows: , , Description of ... Votes ... For ...
Breaking Medicine News(10 mins):Health News:Researchers discover novel method for detecting MIRCERA 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3
... Hodge / Niederer / Cariani /,Lindsay, a leading, national ... Joyce has joined the San Francisco office. Mr. Joyce,will ... board searches throughout the United States., Mr. Joyce ... accomplishments span a range of complex businesses -- large ...
... WASHINGTON, Dec. 5 A report documenting that,the ... and,underperforming is all the evidence Congress should need ... tobacco regulation to that,overburdened agency., That,s the ... President of,60 Plus, a national senior advocacy organization. ...
... Society of,Hematology (ASH), the world,s largest professional society ... made notable,contributions to the genetic understanding of disease. ... Medal, intended to honor an individual,with a distinguished ... will receive the William Dameshek Prize, awarded to ...
... Dec. 5 - The American Society of,Hematology (ASH) is ... recognition of the important role they play in the ... Edward J. Benz,Jr., MD, and Harold R. Roberts, MD, ... in Atlanta., Each year, two awardees, one from ...
... PHILADELPHIAJehovahs Witness patients no longer have to die for ... and Medical Director of the Center for Bloodless Medicine ... Medicine hospital network. Dr. Ford is one of the ... technique to doctors around the world. , One ...
... pollution, especially diesel exhaust , , WEDNESDAY, Dec. 5 (HealthDay ... health damage done by automotive air pollution, especially the ... of improving air quality in Switzerland, which started with ... benefits in lung function for adults as they aged, ...
Other Medicine News:Health News:Dennis Joyce Joins Executive and Board Search Firm Hodge / Niederer / Cariani / Lindsay 2Health News:Leader Urges Congress Not to Worsen FDA Crisis 2Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 2Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 3Health News:Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology 2Health News:New choices for patients: Transfusion-free medicine for Jehovah's Witnesses and transfusion-wary 2Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3
... The Optimal temporary implant for use with ... The pupil dilator type 5S is a ... of the pupil during phacoemulsification. It is ... use. Indication: Expansion of the pupil during ...
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
For use with Crawford Intubation Systems....
... as thread-guide reducing time and trauma in ... is inserted into the nasolacrimal duct and ... it. The probe is then withdrawn leaving ... tubing in place. Canalicular Laceration or Imperforate ...
Medicine Products: